SAVA Stock Falls To New 52-Week Low

Cassava Sciences (SAVA) falls to a new 52-week low. A CUNY report shows “egregious misconduct” in SAVA’s research. The report highlights that they found questionable data management and record keeping. Twenty of the research papers in question provided “key support” for Simufilam, the company’s Alzheimer’s drug. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.

Market On Close

13 Oct 2023

SHARE

ON AIR
6:00 am
Fast Market
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
ON AIR
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now